[Belimumab. A new targeted therapeutic option for lupus erythematosus].

作者信息

Gläser R

机构信息

Hautklinik, Universitätsklinik Schleswig-Holstein, Campus Kiel, Schittenhelmstr. 7, 24105, Kiel, Deutschland.

出版信息

Hautarzt. 2012 Mar;63(3):253-4. doi: 10.1007/s00105-012-2334-y.

DOI:10.1007/s00105-012-2334-y

PMID:22382305

Abstract

摘要

相似文献

[Belimumab. A new targeted therapeutic option for lupus erythematosus].

Hautarzt. 2012 Mar;63(3):253-4. doi: 10.1007/s00105-012-2334-y.

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.

Arthritis Res Ther. 2008;10(5):R109. doi: 10.1186/ar2506. Epub 2008 Sep 11.

Belimumab: a guide to its use in systemic lupus erythematosus.

BioDrugs. 2012 Jun 1;26(3):195-9. doi: 10.2165/11209060-000000000-00000.

Connective tissue diseases: targeting B cells in SLE: good news at last!

Nat Rev Rheumatol. 2011 May;7(5):255-6. doi: 10.1038/nrrheum.2011.48.

Targeting BLyS in systemic lupus erythematosus.

Recent Pat Inflamm Allergy Drug Discov. 2012 May;6(2):91-6. doi: 10.2174/187221312800166831.

Belimumab for the treatment of systemic lupus erythematosus.

Expert Rev Clin Immunol. 2015 Feb;11(2):195-204. doi: 10.1586/1744666X.2015.996550. Epub 2014 Dec 29.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.

Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.

Arthritis Rheum. 2010 Jan;62(1):201-10. doi: 10.1002/art.27189.

Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.

Clin Pharmacol Ther. 2012 Jan;91(1):143-9. doi: 10.1038/clpt.2011.290. Epub 2011 Nov 30.

Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?

Curr Rheumatol Rep. 2012 Aug;14(4):303-9. doi: 10.1007/s11926-012-0254-6.

本文引用的文献

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.

Belimumab: First targeted biological treatment for systemic lupus erythematosus.

J Pharmacol Pharmacother. 2011 Oct;2(4):317-9. doi: 10.4103/0976-500X.85930.

An update on belimumab for the treatment of lupus.

Biologics. 2011;5:33-43. doi: 10.2147/BTT.S13804. Epub 2011 Feb 14.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.

Advances in drug therapy for systemic lupus erythematosus.

BMC Med. 2010 Nov 29;8:77. doi: 10.1186/1741-7015-8-77.

Clinical outcome measures for cutaneous lupus erythematosus.

Lupus. 2010 Aug;19(9):1137-43. doi: 10.1177/0961203310370049.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验